cartiva about cartiva management board investors news careers central to the success of any medical device company is a team of experienced leaders with a proven track record of success cartiva has built an exceptionally talented management team of executives with significant experience in developing and commercializing innovative medical devices and building successful companies timothy patrick president and ceo tim is the president chief executive officer and cofounder of cartiva tim has over  years of successful leadership experience in general management and product commercialization in the medical device industry prior to founding cartiva tim was president and ceo of proxima therapeutics inc a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors proxima was acquired by cytyc corporation in march  prior to cofounding proxima therapeutics in  tim was president of gesco international the leading manufacturer of peripherally inserted central venous catheters acquired by cr bard before serving as president of gesco international he ran two high growth divisions for mcgaw inc an infusion equipment and drug delivery company which was acquired by b braun he also held a number of sales and sales management positions at american hospital supply corporation tim has served on the board of directors of the advanced medical technology association advamed the board of the georgia tech coulter grant committee and on the board of georgia bio tim is an inventor on a number of medical device patents he earned his ba in zoology from miami university in ohio richard knostman vice president operations rick has been vice president operations of cartiva since its founding from  until joining cartiva rick was the vice president operations for proxima therapeutics inc a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors proxima was acquired by cytyc corporation in march  prior to joining proxima rick served as division vice president of operations for bard access systems the world’s leading manufacturer of vascular access catheters and ports and a division of cr bard inc prior to his position with bard he was vice president of operations for gesco international a division of medchem products that was acquired by bard in  rick also worked at baxter healthcare corporation for  years serving in positions that included plant manager division planning manager and production manager an inventor on several patents rick earned a bachelor of science degree in microbiology from the university of arizona tucson deborah moore vice president regulatory quality  clinical affairs debbie has been vice president regulatory quality  clinical affairs of cartiva since its founding debbie has  years of experience in developing regulatory and clinical strategy designing clinical trials and obtaining regulatory approvals and clearances for novel therapeutic technologies from  until joining cartiva debbie was vice president regulatory quality and clinical affairs for proxima therapeutics inc a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors proxima was acquired by cytyc corporation in march  prior to joining proxima she served as the director of regulatory and clinical affairs for dornier medical systems a leader in urologic medical devices she successfully managed dornier’s regulatory submissions multicenter clinical trials and quality system prior to joining dornier she was responsible for regulatory and quality affairs at technomed international a leader in microwave technology for benign prostatic hyperplasia that was later acquired by edap tms sa debbie earned a bachelor of science degree in physics from simmons college and a bachelor of science degree in biomedical engineering from boston university peter pizzo vice president finance and chief financial officer peter has been vice president finance and chief financial officer of cartiva since its founding from  until joining cartiva peter was the vice president finance and chief financial officer of proxima therapeutics inc a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors proxima was acquired by cytyc corporation in march  prior to joining proxima he served in senior financial positions with serologicals corporation a  million publicly traded provider of biological products to life science companies the last two years as vice president of finance and chief financial officer he previously served as vice president of administration and controller of valuemark healthcare systems inc a privately held owneroperator of psychiatric hospitals and in various senior financial positions at hallmark healthcare corporation a publicly traded hospital management company peter currently serves on the board of alimera sciences inc nasdaq alim an ophthalmic pharmaceutical company where he chairs the audit committee and is a member of the nominating and corporate governance committee peter earned a bachelor of science with special attainments in commerce from washington and lee university carribeth ramey vice president engineering and cartiva manufacturing carribeth has been vice president engineering of cartiva since june  she joined cartiva as director engineering and was promoted to vice president in may  from  until joining cartiva carribeth was senior product development engineer at proxima therapeutics inc a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors proxima was acquired by cytyc corporation in march  prior to joining proxima carribeth held research engineering positions at cryolife incorporated focusing on biomaterial and xenograft heart valve development in the areas of hydrodynamics and biomechanics carribeth is an inventor on several patents related to automated injection systems and others related to localized radiation delivery systems carribeth earned a bachelor of science degree in mechanical engineering from the georgia institute of technology and was inducted into the georgia institute of technology’s council of outstanding young engineering alumni bobby singer vice president sales bobby has been vice president sales of cartiva since its acquisition of salumedica llc in  salumedica developed the cartiva synthetic cartilage implant using its proprietary biomaterial technology bobby joined salumedica as vice president of sales in  focusing on international growth in  he was promoted to president and became a member of the company’s board of directors prior to joining salumedica bobby served as vice president of sales for horizon medical products inc a manufacturer and distributor of general and vascular surgery products used in the treatment of oncology patients before leading worldwide sales he held positions as national sales manager regional sales manager and early in his  years with horizon covered the georgia territory as a sales representative bobby earned his bachelor of arts in communication from mercer university katie strother vice president medical education katie has been vice president medical education since november  prior to her current role she served as cartiva’s director clinical affairs since joining cartiva in   katie has over  years of experience in global clinical trial development execution and management  she has significant therapeutic trial experience including orthopaedic devices oncology transplant neurology and endocrinology prior to joining cartiva katie served as a project manager for clinimetrics research associates a full service contract research organization cro focused on study management for biotechnology and early stage pharmaceutical and medical device companies  at clinimetrics she successfully managed phase ii and phase iii global multicenter clinical trials for one of the top  pharmaceutical and biotech companies in the world  prior to joining clinimetrics katie held clinical research positions with quintiles emory university atlanta veteran’s administration medical center and the kerr l white institute for health services research katie earned a bachelor of arts degree in businesseconomics and international relations from agnes scott college cartiva’s board of directors consists of leading investors industry experts and researchers who have successful track records with numerous medical device pharmaceutical and biotechnology companies barbara boyan phd dean school of engineering virginia commonwealth university barbara a cartiva director since  is professor and the alice t and william h goodwin chair in biomedical engineering and dean school of engineering at the virginia commonwealth university in richmond va  in addition she is an emeritus professor in the wallace h coulter department of biomedical engineering at georgia tech and emory university where she held the price gilbert jr chair in tissue engineering from  until  barbara was a georgia research alliance eminent scholar and associate dean for research and innovation in the college of engineering of the georgia institute of technology  she was also director of the children’s healthcare of atlanta’s center for pediatric healthcare technology innovation the atlanta pediatric device consortium and georgia tech’s translational research institute for biomedical engineering and science  barbara is a past chair of the orthopaedic device panel of the fda and a past president of the american association of dental research  she is a fellow in the american association for the advancement of science and the american institute of mechanical and biomedical  barbara holds a ba ma and phd in biology from rice university  ryan drant founder  managing director questa capital management ryan a director since  is the founder and managing director of questa capital a healthcarefocused private investment firm from  to  ryan was a partner at new enterprise associates where he served as a general partner head of the healthcare investing team and a member of nea’s management committee prior to nea he was in the corporate finance group at alex brown  sons and started his career at arthur andersen  co ryan is a fourtime nominee to the forbes midas list of top venture capital investors in addition to cartiva he is currently a director of carticept medical intrinsic therapeutics moximed neotract radiology partners solace therapeutics synchr and spine wave ryan also serves on the board of the medical device manufacturers association he received a bachelor of arts degree in political science from stanford university justin klein partner new enterprise associates nea justin a director since  joined nea in  and is a partner on the healthcare team he focuses on medical device healthcare technology and biopharmaceutical company investments  he serves as a director of advanced cardiac therapeutics  fire intact vascular personal genome diagnostics phasebio pharmaceuticals relievant medsystems senseonics nyse sens vertiflex and vytronus he is also a member of the advisory boards for the national venture capital association’s medical industry group and its medical innovation and competitiveness coalition medic as well as a member of advameds business development committee prior to nea justin worked for the duke university health system—reporting directly to the hospital ceo on health system strategy finance and clinical service unit operations—as duke built one of the nations first and largest healthcare integrated delivery systems justin concurrently earned his md from the duke university school of medicine and his jd from harvard law school he has also served as a member of the board of trustees of duke university where he earned his ab in economics and his bs in biological anthropology and anatomy bob more managing director alta partners bob a director since  joined alta partners a leading life sciences venture capital firm in october  from july  until july  bob was a senior advisor for the bill and melinda gates foundation and led the “global health venture initiative” from  until he joined the gates foundation he was a general partner and a member of the biopharma venture team at frazier healthcare prior to frazier healthcare bob was a partner with domain associates having joined the firm in  as a kauffman fellow and becoming a partner in  from  to bob served as the chief operating officer of small molecule therapeutics a domain portfolio company subsequently purchased by morphochem ag and from  to  was in sales at pharmacia biotech prior to joining pharmacia bob held a research position at somatogen a company developing a recombinant blood substitute that was subsequently bought by baxter while attending business school mr more worked with medvest an earlystage venture group in washington dc bob serves as an advisory board member for greenspring associates okapi ventures the medical industry group of the nvca and the sulpizio family cardiovascular center he is also a past founding board member of the kauffman fellows program bob received his mba from the darden school of business administration at the university of virginia and a ba from middlebury college timothy patrick president and chief executive officer cartiva inc eric stookey chief operating officer osteoremedies llc eric a director since january  has been chief operating officer of osteoremedies llc a company with the first fdacleared modular system for twostage revision of infected hip and knee total joints since march of  prior to joining osteoremedies eric served as the president of the extremities  biologics division at wright medical group inc nasdaqwmgi until august  eric served in various other marketing and sales positions at wright medical group inc since  including as the senior vice president and chief commercial officer from january  to november  as the vice president north american sales from  to january  as the vice president us sales from  until  as the senior director of sales central region from  to  and as the director of marketing for large joint reconstruction products from  to  he was also employed by depuy orthopedics inc from  to  eric who earned his masters of business administration degree from christian brothers university and his bachelor of science degree in business from the indiana university school of business currently serves on the board of amedica corporation nasdaqamda a biomaterial company focused on silicon nitride ceramics new enterprise associates inc nea is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages sectors and geographies with nearly  billion in cumulative committed capital since inception nea invests in technology and healthcare companies at all stages in a company’s lifecycle from seed stage through ipo the firms long track record of successful investing includes more than  portfolio company ipos and more than  acquisitions founded in  windham venture partners is a new york city based venture capital firm focused on healthcare technology with a particular emphasis on medical technology devices and diagnostics and digital health the intersection of healthcare and information technology windham seeks to invest in and partner with companies that are commercializing gamechanging technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors press releases in the news    july   cartiva inc announces multiple presentations at american orthopaedic foot and ankle society annual meeting  april   cartiva inc announces completion of patient enrollment and treatment in study of cartiva® synthetic cartilage implant for pain associated with osteoarthritis of the thumb march   cartiva announces publication of  year clinical data on treating great toe arthritis with cartiva synthetic cartilage implant january   cartiva inc announces financing transactions july   cartiva inc announces first us procedure for fda approved cartiva synthetic cartilage implant july   cartiva inc announces fda premarket approval for cartiva synthetic cartilage implant may   cartiva announces publication of results of cartiva synthetic cartilage implant pivotal study april   cartiva inc announces positive fda advisory committee review of cartiva sci february   cartiva announces first uk patient treated in study of cartiva® sci for pain associated with osteoarthritis of the thumb february   cartiva inc announces tentative date of fda advisory panel review of cartiva sci october   cartiva announces gmp certification by brazils anvisa september   cartiva announces first patient treated in study of cartiva® synthetic cartilage implant for pain associated with osteoarthritis of the thumb september   cartiva announces first patient enrolled in proxifuse post market study july   cartiva announces positive final data from its cartiva sci pivotal trial for great toe arthritis june   cartiva announces first human implant of proxifuse™ hammertoe compression system may   cartiva inc closes  million financing may   cartiva announces submission of final module of pma application for cartiva sci january   cartiva announces k clearance for proxifuse™ hammertoe correction system july   synthetic cartilage offers relief from osteoarthritis cbs news july   synthetic cartilage offers relief from osteoarthritis cbs new york june   new implant offers longterm treatment for arthritis kmsp fox  minneapolis may   moving the market with a firstinclass motionpreserving toe implant the medtech strategist may   fixing painful toe joints with cartiva first synthetic cartilage implant abc  philadelphia pa may   medical director at silver cross hospital back to work four days after foot surgery april   thumb operation that means you can button shirts and open jars again dailymailcom april   this synthetic cartilage can give arthritis sufferers a full range of motion bloomberg businessweek march   synthetic cartilage is now an option for bigtoe arthritis sufferers detroit free press march   medical breakthroughs cartiva toe joint replacement ivanhoe newswire march   new arthritis treatment could be a gamechanger nbc nightly news with lester holt february   new procedure helps treat big toe arthritis wbal baltimore january   new procedure takes away foot pain caused by osteoarthritis fox  chicago november   new toe implant helps injured athletes stay active wralcom november   small implant relieves big toe pain duke health july   implant provides hope for the limping mcknights july   firstofitskind foot surgery performed at strong memorial hospital rochesterfirst cartiva inc is a private medical device company based in the northern atlanta suburb of alpharetta georgia our team consists of highlyskilled professionals who are dedicated to improving the quality of life of patients with osteoarthritis cartilage damage and other musculoskeletal conditions our work environment is highly collaborative and our employees drive cartiva’s friendly fastpaced and energetic environment we offer an engaging small entrepreneurial environment which allows individuals to contribute learn grow and develop we are always looking for motivated individuals who are interested in growth opportunities to join our vibrant team  production operator post date thursday may   job summary the production operator accomplishes various detailed production functions including execution of preventative maintenance activities execution of environmental monitoring activities assembling products or subassemblies according to written instructions and drawings operating hand or power tools and production equipment and performing labeling and packaging activities for finished devices   more  medical education and sales assistant post date monday june   job summary the marketing and sales assistant supports the work of the vp of medical education and the vp of sales via sales and marketing activities and medical education campaigns this position will report directly to the vp medical education and indirectly to the vp of sales and will work closely with both the managers and executives and field sales team to provide organizational and administrative support for the day to day sales and medical education related activities and operations  the primary function of medical education is to provide clinical and technical support for physicians and other internal and external parties  in a medical device company this type of educational support is the foundation of and serves as the primary marketing vehicle for the company the position may include up to  travel in support of company meetings  more  staff accountant post date tuesday july   job summary the staff accountant will be responsible for performing general accounting functions for the company and while supporting the corporate controller in carrying out the responsibilities of the financeaccounting department  this requires familiarization with the operations and procedures of the company as well as a constant level of communication with other departments  more  eastern regional sales manager post date wednesday july   job summary the regional sales manager initial responsibility is to develop an expertise of the cartiva product line surgical procedure and key clinical data pertaining to mtp devices to effectively communicate with new surgeon adopters maintaining key relationships with orthopaedic surgeons in the foot and ankle space is essential to meeting the companys revenue growth goals  other primary responsibilities include managing regional sales distributors and sales professionals   more cartiva inc company profile  bloomberg feedback cartiva inc private company company profile sector health care industry health care facilities  svcs subindustry health care supply chain cartiva inc manufactures medical products the company produces cartilage implants synthetic polymers and hydrogels for cartilage repair and joints relief cartiva serves customers worldwide corporate information address  windward parkway suite  alpharetta ga  united states phone  fax  web url wwwcartivanet from the web d news press releases this synthetic cartilage can give arthritis sufferers a full range of motion apr   cartiva inc announces multiple presentations at american orthopaedic foot and ankle society annual meeting  jul   cartiva inc announces completion of patient enrollment and treatment in study of cartiva® synthetic cartilage implant for apr   sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data cartiva apr   cartiva inc announces completion of patient enrollment and treatment in study of cartiva® synthetic cartilage implant for pain associated with osteoarthritis of the thumb alpharetta ga april   – cartiva inc company a developer of innovative products for treating cartilage damage and osteoarthritis announced today that it has completed enrollment and treatment of all  patients in a multicenter study evaluating the safety and effectiveness of cartiva synthetic cartilage implant sci for first carpometacarpal cmc joint osteoarthritis at the base of the thumb  the study was conducted at nine sites in canada and the united kingdom  basal thumb arthritis is estimated to afflict more than two million american adults and up to onethird of postmenopausal women cartiva sci is a proprietary biocompatible polymer device designed to mimic natural cartilage  in july  the company received premarket approval from the fda for use of cartiva sci in the treatment of osteoarthritis at the base of the great toe  the thumb implant treats osteoarthritis in patients with diseased or damaged articular surface in the first cmc joint it is implanted in the metacarpal base to replace damaged cartilage without destroying or removing healthy tissue  the implant’s design minimizes bone resection while preserving the trapezium  this may provide a quicker less painful recovery than ligament reconstruction tendon interposition lrti surgery or trapeziectomy in late february the company attended a presubmission meeting with the food and drug administration fda to discuss this new indication the company will review the interim sixmonth results at an investigator meeting next month mr philip sauve mb bs frcsed trortho a consultant trauma and orthopaedic surgeon at queen alexandra hospital in portsmouth england who has treated twelve patients with cartiva said “so far we have had good results their pain is reducing their grip strength is increasing and so their function is improving these early results are very promising but we will have to wait to see how the cartiva implant performs over a longer period of time for that group of patients who are maybe still working and still very active i think its a really good option “cartiva sci for cmc is a unique product that could greatly benefit patients suffering from this debilitating condition” said mr l christopher bainbridge mb chb frcsed consultant hand and peripheral nerve surgeon pulvertaft hand centre royal derby hospital and chief uk investigator of the study “with treatment complete we are now focused on patient followup and data analysis” “completion of ontime enrollment was an important milestone for the company” said tim patrick president and ceo cartiva inc “we look forward to working with fda to make cartiva sci for cmc available in the united states for this promising indication” osteoarthritis of the cmc joint osteoarthritis of the cmc joint also known as thumb basal joint arthritisis a debilitating condition impacting  to  of the general population and as many as  of postmenopausal women   it  causes pain swelling instability deformity loss of motion and weakness making it difficult to perform a variety of tasks such as turning doorknobs and opening jars current surgical options for laterstage patients for fail conservative treatments include joint fusion total or partial trapeziectomy arthroplasty or lrti ligament reconstruction and tendon interposition which has been done for more than  years  about cartiva inc based in alpharetta ga cartiva inc develops and markets innovative solutions for patients with cartilage damage and osteoarthritis cartiva’s venture investors include new enterprise associates and windham venture partners additional information is available on the company’s website at wwwcartivanet    back to list cartiva inc private company information  bloomberg july    pm et healthcare equipment and supplies company overview of cartiva inc snapshot people company overview cartiva inc develops and markets medical device solutions for orthopedic surgeons and their patients the company offers cartiva synthetic cartilage implant sci an organic polymerbased biomaterial and a hydrogel implant to mimic natural cartilage and replace the damaged cartilage surface of arthritic joints such as the first metatarsophalangeal joint of the foot the ankle and the knee its cartiva sci restores the natural joint structure in order to relieve pain and provide normal function the company’s product also includes proxifuse hammertoe correction system that is designed for use in the fixation of osteotomies and reconstruction of the lesser toes following correction proce cartiva inc develops and markets medical device solutions for orthopedic surgeons and their patients the company offers cartiva synthetic cartilage implant sci an organic polymerbased biomaterial and a hydrogel implant to mimic natural cartilage and replace the damaged cartilage surface of arthritic joints such as the first metatarsophalangeal joint of the foot the ankle and the knee its cartiva sci restores the natural joint structure in order to relieve pain and provide normal function the company’s product also includes proxifuse hammertoe correction system that is designed for use in the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe claw toe and mallet toe its products help physicians treat osteoarthritis and cartilage injuries and the related pain cartiva inc sells its products through distributors in são paulo brazil halifax canada and sheffield united kingdom the company was founded in  and is based in alpharetta georgia cartiva inc operates as a subsidiary of carticept medical inc detailed description  windward parkwaysuite alpharetta ga united statesfounded in  phone  fax  wwwcartivanet key executives for cartiva inc mr timothy j patrick chief executive officer president and director mr peter j pizzo iii chief financial officer and vice president of finance age  ms deborah j moore vice president of regulatory quality  clinical affairs ms katie e strother director of clinical affairs compensation as of fiscal year  cartiva inc key developments cartiva inc announces the publication of fiveyear data for cartiva synthetic cartilage implant mar   cartiva inc announced the publication of fiveyear data for cartiva synthetic cartilage implant sci in the march issue of foot and ankle international the peerreviewed journal of the american orthopaedic foot and ankle society key findings of the paper include patients experienced durable pain relief achieving a  mean reduction in pain at  years functional improvement was sustained with patients demonstrating a  mean improvement in sporting activities patients experienced a  improvement in range of motion from baseline and patients exhibited a high rate of satisfaction with the treatment cartiva sci is intended to treat painful arthritis at the base of the toeknown as hallux rigidus  the most common arthritic condition in the foot the current standard of care fuses the arthritic joint bones with screws and plates while effective at eliminating pain it permanently prevents movement of the joint cartiva sci is a biocompatible polymer implant designed to have physical properties similar to articular cartilage damaged cartilage is replaced with a small cartiva sci implant that provides a compressible durable lowfriction surface cartiva inc presents at canaccord genuity musculoskeletal conference mar  pm mar   cartiva inc presents at canaccord genuity musculoskeletal conference mar  pm venue westin san diego san diego california united states musculoskeletal clinical regulatory advisers llc assists cartiva inc with obtaining fda pma approval for the companys synthetic cartilage implant sci jul   musculoskeletal clinical regulatory advisers llc mcra announced its role in the successful premarket approval pma application decision by the us food and drug administration fda to approve cartiva incs synthetic cartilage implant sci for the treatment of osteoarthritis in the first metatarsophalangeal mtp joint the cartiva sci is the first hydrogel polymer implant to replace a joint articulating surface ever approved by the fda and the first pma for any product in the forefoot this is the ninth successful pma in which mcra has assisted a client since  including the only three lower extremity pmas similar private companies by industry company name region decimal inc united states  genesystems inc united states  imaging llc united states st century scientific inc united states x corporation united states recent private companies transactions typedate target private placement november    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact cartiva inc please visit wwwcartivanet company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close cartiva inc announces fda premarket approval for cartiva synthetic cartilage implant  business wire cartiva inc announces fda premarket approval for cartiva synthetic cartilage implant first pma approved alternative to fusion for arthritis of the big toe joint download windows media video quicktime mpeg video loading media player cartiva sci surgical animation paginationprevious paginationnext cartiva sci surgical animation windows media video quicktime mpeg video cartiva synthetic cartilage implant sci photo business wire full size small preview thumbnail cartiva synthetic cartilage implant sci photo business wire full size small preview thumbnail cartiva synthetic cartilage implant sci photo business wire full size small preview thumbnail small preview thumbnail cartiva faq doc cartiva vs fusion pdf july    am eastern daylight time alpharetta gabusiness wirecartiva inc a developer of innovative products for the treatment of cartilage damage and osteoarthritis announced today that it received premarket approval pma from the us food and drug administration fda for its cartiva synthetic cartilage implant sci for arthritis of the big toe joint the approval allows the company to begin marketing in the united states the first synthetic cartilage device approved by the fda cartiva sci is intended for the treatment of painful arthritis at the base of the big toe the most common arthritic condition in the foot the current standard of care involves fusing the bones in the arthritic joint with screws and plates while fusion is an effective procedure for eliminating pain it permanently prevents movement of the joint the cartiva sci device an alternative to fusion is a biocompatible biomedical polymer implant designed to have physical properties similar to those of articular cartilage damaged cartilage is replaced with a small cartiva sci implant that provides a cartilagelike compressible lowfriction and durable bearing surface the implant provides pain relief and improves both function and motion the fda’s decision was supported by the motion clinical study a patient multicenter prospective randomized study comparing cartiva sci to fusion – the largest study ever conducted for this condition key findings from the level i clinical study include the cartiva patient group demonstrated clinical success of  for the composite primary endpoint pain function and safety at  months compared to  success for the fusion group cartiva patients achieved a  reduction in median pain cartiva patients demonstrated a  improvement in median function of sporting activities and  improvement in activities of daily living cartiva patients experienced a  improvement in range of motion from baseline “the landmark motion study clearly shows cartiva sci to be a safe and effective alternative to fusion for patients wishing to maintain motion in their great toe” said dr judith baumhauer professor and associate chair of academic affairs university of rochester medical center and principal investigator on the motion study “based on these compelling results i have eagerly awaited the fda approval and the ability to offer this treatment option to my patients” cartiva sci has been approved for use outside the united states since  and is currently available in europe canada and brazil to date more than  implants have been used it is performed in a simple outpatient procedure lasting approximately  minutes unlike a fusion procedure patients may begin weight bearing immediately as tolerated “before cartiva sci the options we could provide to patients with osteoarthritis of the great toe were limited as the fusion procedure often necessitates sacrificing range of motion to get pain relief” said dr mark glazebrook of the queen elizabeth ii health sciences centre in halifax nova scotia who uses cartiva sci in his practice “due to the simplicity of the procedure speed of recovery and range of motion benefits i see that patients are relieved to have this option available to them and the majority are electing cartiva over fusion” “we are thrilled with the approval of cartiva sci and appreciate the hard work and collaboration of the us food and drug administration orthopaedic branch were grateful to our clinical investigators their study coordinators and of course our patients in helping us reach this critical milestone” said tim patrick president and ceo cartiva inc “we look forward to introducing cartiva sci at the american orthopaedic foot and ankle society annual meeting in toronto later this month about cartiva inc based in alpharetta ga cartiva inc develops and markets innovative solutions for patients with cartilage damage and osteoarthritis cartiva’s venture investors include new enterprise associates windham venture partners and domain associates additional information is available on the company’s website at wwwcartivanet contacts company contactcartiva incpeter pizzo chief financial officerormedia contactmslgroupwendy ryan cartivamslgroupcom contacts company contactcartiva incpeter pizzo chief financial officerormedia contactmslgroupwendy ryan cartivamslgroupcom search advanced news search advanced news search log in sign up   cartiva inc signs distribution agreement with canadian distributor rehab matrix canada inc  business wire cartiva inc signs distribution agreement with canadian distributor rehab matrix canada inc november    am eastern standard time alpharetta ga  halifax nova scotiabusiness wirecartiva inc a developer of innovative products for the treatment of cartilage injuries and osteoarthritis today announced the signing of a distribution agreement with foot and ankle orthopedic medical device distributor rehab matrix canada inc “rehab matrix” under the terms of the agreement rehab matrix will exclusively distribute the company’s cartiva synthetic cartilage implant sci throughout canada “rehab matrix is an ideal partner as they have longestablished relationships with many of the leading foot and ankle surgeons in canada” said timothy j patrick president and chief executive officer of cartiva “we look forward to working with the rehab matrix team as they formally launch the product later this year” “we are committed to bringing the most innovative technologies to the canadian foot and ankle market” said curtis northrup president of rehab matrix “preliminary feedback about cartiva sci from clinicians has been extremely positive and we are excited to establish cartiva as an attractive alternative to fusion the cartiva procedure maintains range of motion by replacing the damaged cartilage in the affected joint with a smooth resilient cartilagelike polymer while fusion is effective at reducing pain caused by advanced arthritis in the great toe it prohibits natural joint motion by fusing the joint with plates and screws cartiva patients also avoid the inconvenience of wearing a hard cast for six to eight weeks following a fusion procedure “we are seeing increasing interest in cartiva sci in canada where over  of the patients in our clinical trial were treated” added patrick “we are confident that canadian surgeons will welcome the addition of this innovative technology as a treatment option for their patients” about cartiva incbased in alpharetta ga and spun off from carticept medical inc in december  cartiva inc develops and markets innovative solutions for patients with osteoarthritis or cartilage damage additional information is available on the company’s website at wwwcartivanet contacts cartiva incpeter pizzo chief financial officer contacts cartiva incpeter pizzo chief financial officer search advanced news search advanced news search log in sign up cartiva inc announces multiple presentations at american orthopaedic foot and ankle society annual meeting   extremities cartiva inc announces multiple presentations at american orthopaedic foot and ankle society annual meeting  posted by josh sandberg on  weeks ago more in extremities paragon ® announces launch of jaws™ nitinol staple system to address fracture and osteotomy fixation of the foot  day ago paragon ® expands innovative product portfolio with the launch of the promo™ triplanar hallux valgus correction system  days ago orthopaedic surgeons warn parents and young children about the dangers of trampolines  week ago share this story with your networkfacebooktwittergooglepinterestjuly   alpharetta ga–business wire–cartiva inc company a developer of innovative products for treating cartilage damage and osteoarthritis announced today that clinical data on its cartiva synthetic implant sci will be presented at the american orthopaedic foot and ankle society aofas annual meeting taking place july  at the washington state convention center in seattle washington the aofas is a medical specialty society comprised of more than  orthopaedic surgeons from the us and abroad who specialize in the care of patients with injuries diseases and other conditions of the foot and ankle the presentations include friday july th  am to  am podium presentation by mark a glazebrook msc md phd frcsc “revision of implant to great toe fusion did we “burn a bridge” with a synthetic implant hemiarthroplasty” saturday july th  am to  am podium presentation by judith f baumhauer md mph “correlation of hallux rigidus coughlin grade with first mtp motion intraoperative cartilage loss and treatment success for st mtp arthrodesis and hemiarthroplasty” this abstract was selected by the aofas program committee as one of three finalists for the prestigious roger a mann award the mann award is given in recognition of the best clinical paper accepted for presentation at the annual meeting the winner of the award will be announced during the meeting on friday july th saturday july th  am to  am podium presentation by andrew j goldberg obe md mbbs frcs frcs trorth “the influence of patient factors on the outcome of synthetic cartilage implant hemiarthroplasty versus first metatarsophalangeal joint arthrodesis in advanced hallux rigidus” in addition the company will sponsor a symposium on friday july th from  am to  am level  rooms    entitled “the difference is data™ – cartiva synthetic cartilage implant for hallux rigidus” the symposium’s faculty includes judith f baumhauer md mph michael j coughlin md timothy r daniels md frcsc mark a glazebrook msc md phd frcsc david b thordarson md and keith l wapner md the company invites all conference attendees to visit cartiva exhibitor booth  for ongoing demonstrations of its cartiva sci technology about cartiva inc based in alpharetta ga cartiva inc develops and markets innovative solutions for patients with cartilage damage and osteoarthritis cartiva’s venture investors include new enterprise associates and windham venture partners additional information is available on the company’s website at wwwcartivanet contacts cartiva inc peter pizzo  chief financial officer leave a comment cancel your email address will not be published required fields are marked message name  email address  website notify me of followup comments by email notify me of new posts by email recent nuvasive reports second quarter  financial resultsnuvasive announces new organizational structure to drive growth and profitability goalsglobal orthobiologics market forecast camber spine technologies announces exceeding the th implantation of enza™ zeroprofile alifzimmer biomet reports second quarter  financial resultspopular the single protein injection which could replace the need for knee surgery for osteoarthritis sufferers  comments pegasus biologics is insolvent closing their doors  comments the spineblogger  comments nuvasive ceo no sign of economic hit to spinal devices  comments win an ipod shuffle  comments tweets my tweets follow us lets connect on any of these social networks subscribe to blog via email enter your email address to subscribe to this blog and receive notifications of new posts by email email address polls with the acquisition of spinal elements what do you expect to be the fate of amendia file for ipo get acquired struggle to integrate  grow status quo increased growth but stay private view results  loading  polls archive orthospinenews